Lendormin D® Tablet (Drug Use Result Survey)
Completed
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- Drug: Lendormin D tablets
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 485
- Registration Number
- NCT02224014
Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT02222961
Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT02222987
Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension
Phase 2
Completed
- Conditions
- Hypertension, Pulmonary
- Interventions
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 71
- Registration Number
- NCT02223481
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT02223260
- Locations
- 🇫🇷
1160.105.33001 Boehringer Ingelheim Investigational Site, Paris, France
🇨🇦1160.105.10002 Boehringer Ingelheim Investigational Site, Ottawa, Ontario, Canada
🇨🇦1160.105.10003 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada
Relative Bioavailability of BI 671800 HEA in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 671800 HEA particulateDrug: BI 671800 HEA delayed release (enteric coated) tabletDrug: BI 671800 HEA solution
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10
- Registration Number
- NCT02222233
Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 1744 CL/BI 54903 XX FDCDrug: BI 54903 XXDrug: BI 1744 CL
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02222428
Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02222168
- Locations
- 🇩🇪
1289.22.1 Boehringer Ingelheim Investigational Site, Berlin, Germany
Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 671800 ED, 100 mg capsulesDrug: BI 671800 HEA EC, 200 mg tabletsDrug: BI 671800 HEA, 200 mg tabletsDrug: BI 671800 HEA, 50 mg tabletsOther: Standard meal
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02221388
Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT02220647
© Copyright 2025. All Rights Reserved by MedPath